Avoid common mistakes on your manuscript.
1 Correction to: Drug Safety https://doi.org/10.1007/s40264-019-00797-3
In the original publication of this article, the following correction should be noted in Table 5.
The 95% CI for serious infections in the Ustekinumab −MTX group under PsA should read 0.8–3.5 and not 0.8–3.5.5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Ghosh, S., Gensler, L.S., Yang, Z. et al. Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Saf 42, 809 (2019). https://doi.org/10.1007/s40264-019-00816-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40264-019-00816-3